Instil Bio, Inc. financial data

Symbol
TIL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
3963 Maple Avenue, Suite 350, Dallas, TX
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.44K % +21.7%
Debt-to-equity 52.3 % +28.6%
Return On Equity -39.7 % +32.1%
Return On Assets -26.1 % +37.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.53M shares +0.34%
Common Stock, Shares, Outstanding 6.53M shares +0.34%
Entity Public Float 38.6M USD +12.2%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 6.51M shares +0.1%
Weighted Average Number of Shares Outstanding, Diluted 6.51M shares +0.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 20.7M USD -76.9%
General and Administrative Expense 44.2M USD -7.03%
Operating Income (Loss) -73.5M USD +53.8%
Nonoperating Income (Expense) -2.86M USD -397%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -156M USD +30.7%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -74.1M USD +52.5%
Earnings Per Share, Basic -11.4 USD/shares +52.5%
Earnings Per Share, Diluted -11.4 USD/shares +52.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 8.81M USD -4.24%
Marketable Securities, Current 141M USD -35%
Other Assets, Current 959K USD -63.2%
Assets, Current 124M USD -22.6%
Property, Plant and Equipment, Net 129M USD -6.69%
Operating Lease, Right-of-Use Asset 934K USD -60.9%
Other Assets, Noncurrent 8.76M USD +1270%
Assets 264M USD -19.1%
Accounts Payable, Current 659K USD -45.6%
Employee-related Liabilities, Current 2.69M USD +162%
Liabilities, Current 7.9M USD -25.2%
Operating Lease, Liability, Noncurrent 1.02M USD -64.7%
Other Liabilities, Noncurrent 83K USD +3.75%
Liabilities 94.1M USD -5.68%
Accumulated Other Comprehensive Income (Loss), Net of Tax -228K USD +34.5%
Retained Earnings (Accumulated Deficit) -655M USD -12.8%
Stockholders' Equity Attributable to Parent 169M USD -25%
Liabilities and Equity 264M USD -19.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.4M USD +58.5%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 9.24M USD -36.4%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 6.53M shares +0.34%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 10.6M USD -0.57%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.73M USD +17.1%
Deferred Tax Assets, Valuation Allowance 141M USD +11.6%
Deferred Tax Assets, Gross 143M USD +12.6%
Operating Lease, Liability 2.7M USD -41.7%
Depreciation 3.6M USD -25%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -74M USD +52.5%
Lessee, Operating Lease, Liability, to be Paid 3.04M USD -39.7%
Property, Plant and Equipment, Gross 134M USD -8.24%
Operating Lease, Liability, Current 1.68M USD -3.89%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.22M USD -39%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.82M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 337K USD -17.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.82M USD +43.1%
Deferred Tax Assets, Operating Loss Carryforwards 95.8M USD +8.33%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.34M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.22M USD -4.17%
Operating Lease, Payments 2.28M USD -1.26%
Additional Paid in Capital 825M USD +2.18%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 993K USD -44.1%
Deferred Tax Assets, Net of Valuation Allowance 1.19M USD
Share-based Payment Arrangement, Expense 17.3M USD -5%
Interest Expense 6.55M USD +160%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%